Aryl-substituted imidazoles
US9822100B2 · kind B2 · utility
1Cited by
5References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2016 |
| Grant date | Nov 21, 2017 |
| Priority date | — |
| Expiry date | Jan 8, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D233/22
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.